Hypoxic human cancer cells are sensitized to BH-3 mimetic–induced apoptosis via downregulation of the Bcl-2 protein Mcl-1
Luke R.E. Harrison, … , Guy Makin, Caroline Dive
Luke R.E. Harrison, … , Guy Makin, Caroline Dive
Published February 14, 2011
Citation Information: J Clin Invest. 2011;121(3):1075-1087. https://doi.org/10.1172/JCI43505.
View: Text | PDF
Research Article Oncology

Hypoxic human cancer cells are sensitized to BH-3 mimetic–induced apoptosis via downregulation of the Bcl-2 protein Mcl-1

Abstract

Solid tumors contain hypoxic regions in which cancer cells are often resistant to chemotherapy-induced apoptotic cell death. Therapeutic strategies that specifically target hypoxic cells and promote apoptosis are particularly appealing, as few normal tissues experience hypoxia. We have found that the compound ABT-737, a Bcl-2 homology domain 3 (BH-3) mimetic, promotes apoptotic cell death in human colorectal carcinoma and small cell lung cancer cell lines exposed to hypoxia. This hypoxic induction of apoptosis was mediated through downregulation of myeloid cell leukemia sequence 1 (Mcl-1), a Bcl-2 family protein that serves as a biomarker for ABT-737 resistance. Downregulation of Mcl-1 in hypoxia was independent of hypoxia-inducible factor 1 (HIF-1) activity and was consistent with decreased global protein translation. In addition, ABT-737 induced apoptosis deep within tumor spheroids, consistent with an optimal hypoxic oxygen tension being necessary to promote ABT-737–induced cell death. Tumor xenografts in ABT-737–treated mice also displayed significantly more apoptotic cells within hypoxic regions relative to normoxic regions. Synergies between ABT-737 and other cytotoxic drugs were maintained in hypoxia, suggesting that this drug may be useful in combination with chemotherapeutic agents. Taken together, these findings suggest that Mcl-1–sparing BH-3 mimetics may induce apoptosis in hypoxic tumor cells that are resistant to other chemotherapeutic agents and may have a role in combinatorial chemotherapeutic regimens for treatment of solid tumors.

Authors

Luke R.E. Harrison, Dimitra Micha, Martin Brandenburg, Kathryn L. Simpson, Christopher J. Morrow, Olive Denneny, Cassandra Hodgkinson, Zaira Yunus, Clare Dempsey, Darren Roberts, Fiona Blackhall, Guy Makin, Caroline Dive

×

Figure 1

Effects of ABT-737 in cancer cell lines under normoxic and hypoxic conditions.

Options: View larger image (or click on image) Download as PowerPoint
Effects of ABT-737 in cancer cell lines under normoxic and hypoxic condi...
(A) H146, H82 SCLC, and HCT116 CRC cells were incubated in normoxia or hypoxia (1% O2) for 18 hours, after which they were exposed to a range of ABT-737 concentrations under continuous normoxia or hypoxia for 72 hours prior to determination of IC50 values using the resazurin assay. (B) H146 SCLC and H82 SCLC cells were preincubated for 18 hours in normoxia or hypoxia (1% O2) before treatment with ABT-737 at 89.1 nM and 12.2 μM, respectively, for the indicated times. Control cells were exposed to an equivalent concentration of drug diluent (DMSO) in normoxia or hypoxia at selected time points. HCT116 CRC cancer cells were preincubated for 18 hours in normoxia or hypoxia and treated with the indicated ABT-737 concentrations or DMSO vehicle with maintained hypoxia or normoxia and assessed 24 hours later. The percentage of cells undergoing apoptosis was determined by DAPI staining and counting at least 100 cells per field in duplicate. Data are mean ± SEM of 3 independent experiments. *P < 0.05, **P < 0.01; (Student’s 2-tailed t test).